CMPX Stock Overview
A clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Compass Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.60 |
| 52 Week High | US$3.45 |
| 52 Week Low | US$1.15 |
| Beta | 0.73 |
| 1 Month Change | 7.38% |
| 3 Month Change | -5.88% |
| 1 Year Change | -50.62% |
| 3 Year Change | -63.64% |
| 5 Year Change | n/a |
| Change since IPO | -81.18% |
Recent News & Updates
Shareholder Returns
| CMPX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.9% | 0.7% | 1.2% |
| 1Y | -50.6% | 5.0% | 27.7% |
Return vs Industry: CMPX underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: CMPX underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| CMPX volatility | |
|---|---|
| CMPX Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CMPX's share price has been volatile over the past 3 months.
Volatility Over Time: CMPX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 32 | Vered Bisker-Leib | www.compasstherapeutics.com |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies.
Compass Therapeutics, Inc. Fundamentals Summary
| CMPX fundamental statistics | |
|---|---|
| Market cap | US$220.14m |
| Earnings (TTM) | -US$45.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs CMPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMPX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$45.44m |
| Earnings | -US$45.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CMPX perform over the long term?
See historical performance and comparison